237 related articles for article (PubMed ID: 17535433)
41. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
43. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
44. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
[TBL] [Abstract][Full Text] [Related]
45. Expression level of beta protein 1 mRNA in Chinese breast cancer patients: a potential molecular marker for poor prognosis.
Yu M; Yang Y; Shi Y; Wang D; Wei X; Zhang N; Niu R
Cancer Sci; 2008 Jan; 99(1):173-8. PubMed ID: 17999690
[TBL] [Abstract][Full Text] [Related]
46. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
47. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
48. Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma.
Girault I; Andrieu C; Tozlu S; Spyratos F; Bièche I; Lidereau R
Cancer Lett; 2004 Nov; 215(1):101-12. PubMed ID: 15374639
[TBL] [Abstract][Full Text] [Related]
49. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
[TBL] [Abstract][Full Text] [Related]
50. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.
Dai H; van't Veer L; Lamb J; He YD; Mao M; Fine BM; Bernards R; van de Vijver M; Deutsch P; Sachs A; Stoughton R; Friend S
Cancer Res; 2005 May; 65(10):4059-66. PubMed ID: 15899795
[TBL] [Abstract][Full Text] [Related]
51. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
52. Concordance among gene-expression-based predictors for breast cancer.
Fan C; Oh DS; Wessels L; Weigelt B; Nuyten DS; Nobel AB; van't Veer LJ; Perou CM
N Engl J Med; 2006 Aug; 355(6):560-9. PubMed ID: 16899776
[TBL] [Abstract][Full Text] [Related]
53. Transcriptome characterization of human mammary cell lines expressing different levels of ERBB2 by serial analysis of gene expression.
dos Santos ML; Palanch CG; Salaorni S; Da Silva WA; Nagai MA
Int J Oncol; 2006 Jun; 28(6):1441-61. PubMed ID: 16685446
[TBL] [Abstract][Full Text] [Related]
54. Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer.
Zhang J; Gu L; Zhao LJ; Zhang XF; Qiu L; Li Z
Chin Med J (Engl); 2011 Sep; 124(18):2894-8. PubMed ID: 22040499
[TBL] [Abstract][Full Text] [Related]
55. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.
Gunnarsson C; Jerevall PL; Hammar K; Olsson B; Nordenskjöld B; Jansson A; Stål O
Breast Cancer Res Treat; 2008 Mar; 108(1):35-41. PubMed ID: 17457667
[TBL] [Abstract][Full Text] [Related]
56. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome.
Dairkee SH; Nicolau M; Sayeed A; Champion S; Ji Y; Moore DH; Yong B; Meng Z; Jeffrey SS
Oncogene; 2007 Sep; 26(43):6269-79. PubMed ID: 17471242
[TBL] [Abstract][Full Text] [Related]
57. [Molecular portrait of breast cancer with sub-classification of breast tumor].
Siegelmann-Danieli N; Stein ME; Wallach N
Harefuah; 2007 Jan; 146(1):48-52, 77-8. PubMed ID: 17294849
[TBL] [Abstract][Full Text] [Related]
58. The mRNA expression of DAP3 in human breast cancer: correlation with clinicopathological parameters.
Wazir U; Jiang WG; Sharma AK; Mokbel K
Anticancer Res; 2012 Feb; 32(2):671-4. PubMed ID: 22287761
[TBL] [Abstract][Full Text] [Related]
59. Search for a gene expression signature of breast cancer local recurrence in young women.
Servant N; Bollet MA; Halfwerk H; Bleakley K; Kreike B; Jacob L; Sie D; Kerkhoven RM; Hupé P; Hadhri R; Fourquet A; Bartelink H; Barillot E; Sigal-Zafrani B; van de Vijver MJ
Clin Cancer Res; 2012 Mar; 18(6):1704-15. PubMed ID: 22271875
[TBL] [Abstract][Full Text] [Related]
60. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.
Desmedt C; Ouriaghli FE; Durbecq V; Soree A; Colozza MA; Azambuja E; Paesmans M; Larsimont D; Buyse M; Harris A; Piccart M; Martiat P; Sotiriou C
Int J Cancer; 2006 Dec; 119(11):2539-45. PubMed ID: 16929516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
